Skip to product information
1 of 1
New Year Badge
🏷️ Save up to 70% on all books, discount auto applied

ESMO Melanoma & Other Skin Cancers: Essentials for Clinicians

ESMO Melanoma & Other Skin Cancers: Essentials for Clinicians

Regular price $25.00 USD
Regular price $20.00 USD Sale price $25.00 USD
Sale Sold out
Girl in a jacket

Instant Download

Your unique download link appears right after you complete your purchase, and is also sent instantly to the email address you provided.

ISBN

9788894446531

Edition

Authors

Adam I. Riker

Publisher

Other Publisher

Published date

Other Publisher

Size

23 MB

Pages count

652

Table of Contents & Sample Chapter

View full details

by Paolo A. Ascierto, Iwona Lugowska, Ruth Plummer
Melanoma is the most aggressive form of skin cancer and its incidence has been rising over the last decade. Fortunately, advances in disease knowledge through research and innovation, as well as a multidisciplinary treatment strategy, has placed clinicians in a position to better manage melanoma patients and changed how we evaluate and treat them.  Nonetheless, there is much more that needs to be discovered to improve outcomes and increase awareness.
In this scenario, this first edition of Melanoma & Other Skin Cancers: Essentials for Clinicians has been designed to provide an up-to-date and multidisciplinary overview of the epidemiology, pathology, and current and innovative evidence-based treatment options for patients with all stages of melanoma and other skin cancers.
This extensive book brings together leading skin cancer researchers and clinicians from across the world; the content is organised in two sections. Part A, ‘What every oncologist should know’, seven chapters, provides a comprehensive overview of the epidemiology, prevention, screening and surveillance as well as staging, prognostic factors and current treatment of melanoma. Part B, ’More advanced knowledge’, six chapters, discusses the advances in melanoma and skin cancer research and treatment, exploring the pathology and molecular profile, predictive biomarkers and, finally, emerging targets and personalised medicine.